Clinical trial
Targeting Attentional and Cognitive Control to Enhance the Transdiagnostic Treatment of Repetitive Negative Thinking
NCT04225624 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting Attentional and Cognitive Control to Enhance the Transdiagnostic Treatment of Repetitive Negative Thinking
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- April 30, 2021
- Completion date
- April 9, 2025
- Enrollment
- 65 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.